Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
Integration of real-world evidence from different data sources in health technology assessment
J Pharm Pharm Sci. 2023 Jul 17;26:11460. doi: 10.3389/jpps.2023.11460. eCollection 2023.ABSTRACTReal-world evidence (RWE) is being increasingly used by a wide range of stakeholders involved in the therapeutic product lifecycle but remains underutilized in the health technology assessment (HTA) process. RWE aims to fill the current evidence gaps, reduce the uncertainty around the benefits of medical technologies, and better understand the long-term impact of health technologies in real-world conditions. Despite the minimal use of RWE in some elements of HTA, there has been a larger push to further utilize RWE in the HTA pro...
Source: J Pharm Pharm Sci - August 2, 2023 Category: Drugs & Pharmacology Authors: Pooyeh Graili Jason R Guertin Kelvin K W Chan Mina Tadrous Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
Conclusion: These results suggest that, compared with other drugs, COVID-19 vaccination is associated with a higher frequency of IgAN. Monitoring of gross hematuria following COVID-19 vaccination should be needed.PMID:37456806 | PMC:PMC10348063 | DOI:10.3389/jpps.2023.11453 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - July 17, 2023 Category: Drugs & Pharmacology Authors: Hiroka Nakao Takenao Koseki Koki Kato Shigeki Yamada Naotake Tsuboi Kazuo Takahashi Tomohiro Mizuno Source Type: research
